348 related articles for article (PubMed ID: 18349432)
1. Modeling the logistics of response to anthrax bioterrorism.
Zaric GS; Bravata DM; Cleophas Holty JE; McDonald KM; Owens DK; Brandeau ML
Med Decis Making; 2008; 28(3):332-50. PubMed ID: 18349432
[TBL] [Abstract][Full Text] [Related]
2. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies.
Bravata DM; Zaric GS; Holty JE; Brandeau ML; Wilhelm ER; McDonald KM; Owens DK
Biosecur Bioterror; 2006; 4(3):244-62. PubMed ID: 16999586
[TBL] [Abstract][Full Text] [Related]
3. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.
Schmitt B; Dobrez D; Parada JP; Kyriacou DN; Golub RM; Sharma R; Bennett C
Arch Intern Med; 2007 Apr; 167(7):655-62. PubMed ID: 17420423
[TBL] [Abstract][Full Text] [Related]
4. An ounce of prevention is worth a pound of cure: improving communication to reduce mortality during bioterrorism responses.
Brandeau ML; Zaric GS; Freiesleben J; Edwards FL; Bravata DM
Am J Disaster Med; 2008; 3(2):65-78. PubMed ID: 18522248
[TBL] [Abstract][Full Text] [Related]
5. Planning the bioterrorism response supply chain: learn and live.
Brandeau ML; Hutton DW; Owens DK; Bravata DM
Am J Disaster Med; 2007; 2(5):231-47. PubMed ID: 18491839
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of strategies to reduce mortality from an intentional release of aerosolized anthrax spores.
Braithwaite RS; Fridsma D; Roberts MS
Med Decis Making; 2006; 26(2):182-93. PubMed ID: 16525172
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.
Kyriacou DN; Dobrez D; Parada JP; Steinberg JM; Kahn A; Bennett CL; Schmitt BP
Biosecur Bioterror; 2012 Sep; 10(3):264-79. PubMed ID: 22845046
[TBL] [Abstract][Full Text] [Related]
8. Medical counterbioterrorism: the response to provide anthrax prophylaxis to New York City US Postal Service employees.
Partridge R; Alexander J; Lawrence T; Suner S
Ann Emerg Med; 2003 Apr; 41(4):441-6. PubMed ID: 12658240
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax.
Fowler RA; Sanders GD; Bravata DM; Nouri B; Gastwirth JM; Peterson D; Broker AG; Garber AM; Owens DK
Ann Intern Med; 2005 Apr; 142(8):601-10. PubMed ID: 15838066
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of public health interventions for Anthrax: a report to the secretary's council on Public Health Preparedness.
Wein LM; Craft DL;
Biosecur Bioterror; 2005; 3(4):348-56. PubMed ID: 16366844
[TBL] [Abstract][Full Text] [Related]
11. Anthrax attack at the United States Capitol. Front line thoughts.
Anderson A; Eisold JF
AAOHN J; 2002 Apr; 50(4):170-3. PubMed ID: 11979645
[TBL] [Abstract][Full Text] [Related]
12. Implementing the cities readiness initiative: lessons learned from Boston.
Koh HK; Elqura LJ; Judge CM; Jacob JP; Williams AE; Crowther MS; Serino RA; Auerbach JM
Disaster Med Public Health Prep; 2008 Mar; 2(1):40-9. PubMed ID: 18388657
[TBL] [Abstract][Full Text] [Related]
13. Medical countermeasures to protect humans from anthrax bioterrorism.
Bouzianas DG
Trends Microbiol; 2009 Nov; 17(11):522-8. PubMed ID: 19781945
[TBL] [Abstract][Full Text] [Related]
14. Logistics modelling: improving resource management and public information strategies in Florida.
Walsh DM; Van Groningen C; Craig B
J Bus Contin Emer Plan; 2011 Oct; 5(3):246-56. PubMed ID: 22130343
[TBL] [Abstract][Full Text] [Related]
15. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
Vietri NJ; Purcell BK; Tobery SA; Rasmussen SL; Leffel EK; Twenhafel NA; Ivins BE; Kellogg MD; Webster WM; Wright ME; Friedlander AM
J Infect Dis; 2009 Feb; 199(3):336-41. PubMed ID: 19099484
[TBL] [Abstract][Full Text] [Related]
16. Inhalational anthrax.
Cuneo BM
Respir Care Clin N Am; 2004 Mar; 10(1):75-82. PubMed ID: 15062228
[TBL] [Abstract][Full Text] [Related]
17. Anthrax countermeasures: current status and future needs.
Borio LL; Gronvall GK
Biosecur Bioterror; 2005; 3(2):102-12. PubMed ID: 16000041
[TBL] [Abstract][Full Text] [Related]
18. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
[TBL] [Abstract][Full Text] [Related]
19. A decision framework for coordinating bioterrorism planning: lessons from the BioNet program.
Manley DK; Bravata DM
Am J Disaster Med; 2009; 4(1):49-57. PubMed ID: 19378669
[TBL] [Abstract][Full Text] [Related]
20. The mayor, his troops, and the health of a city.
Tully S
Fortune; 2001 Nov; 144(11):138-42. PubMed ID: 11816774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
